Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease

Dopamine-Based Approaches
Boehringer Ingelheim Pharmaceuticals
Parkinson Disease
Drug
pramipexole

This is a double blind, placebo-controlled clinical trial of 15 months duration designed to examine early Mirapex (pramipexole) treatment vs. delayed Mirapex (pramipexole) treatment in patients with new onset Parkinson's disease.

Link to the current ClinicalTrials.gov record.
Agency: 
Boehringer Ingelheim Pharmaceuticals
Phase: 
Phase IV
Study Design: 
Treatment, Parallel Assignment, Safety/Efficacy Study
Condition: 
Parkinson Disease
Intervention type: 
Drug
Intervention Name: 
pramipexole
Information Retrieved from Source: 
Wednesday, 24 December 2008